Genes Associated with m6A Modifications Indicate Prognostic Risk and Immune Modulation in Lung Adenocarcinoma - Top-Institutions - MDSpire

Genes Associated with m6A Modifications Indicate Prognostic Risk and Immune Modulation in Lung Adenocarcinoma

  • By

  • Xiaoxing Liu

  • Shanshan Li

  • Min Zhou

  • Ning Ding

  • Jinzhong Chen

  • Ning Zhou

  • January 16, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Cancer Genomics
    • Epigenetics
    • Immuno-oncology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Cancer Epigenetics
    • Translational Research

  • #3

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Cancer Genomics
    • Epigenetics
    • Immunotherapy

  • #4

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Oncology
    • Molecular Biology
    • Epigenetics

Original Source(s)

Genes Associated with m6A Modifications Indicate Prognostic Risk and Immune Modulation in Lung Adenocarcinoma

  • by Xiaoxing Liu, Shanshan Li, Min Zhou, Ning Ding, Jinzhong Chen, Ning Zhou

  • January 16, 2026

Related Content

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

Case Report: Intramedullary solitary fibrous tumor at the C7-T1 level diagnosed by STAT6 and treated with maximal safe resection

Association between EAT-Lancet diet adherence and cancer incidence/mortality: a systematic review and meta-analysis